PNC Financial Services Group
AVBP icon

PNC Financial Services Group’s ArriVent BioPharma AVBP Stock Holding History

PNC Financial Services Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.43K Sell
214
-112
-34% -$3.31K ﹤0.01% 4228
2026
Q1 		$7.52K Buy
326
+189
+138% +$4.27K ﹤0.01% 4076
2025
Q4 		$2.76K Buy
137
+129
+1,613% +$2.69K ﹤0.01% 4446
2025
Q3 		$148 Buy
+8
New +$157 ﹤0.01% 4965

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PNC Financial Services Group's AVBP Position: Q2 2026 in Review

PNC Financial Services Group reduced its ArriVent BioPharma (AVBP) stake by 34% in Q2 2026, selling an estimated $3.31K and leaving 214 shares worth $7.43K. The position accounts for ﹤0.01% of the portfolio, ranked #4228.

PNC Financial Services Group first reported a position in AVBP in Q3 2025 and has held it in 4 quarters since. The position peaked at $7.52K in Q1 2026. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • PNC Financial Services Group held 214 shares of ArriVent BioPharma worth $7.43K as of Q2 2026.
  • PNC Financial Services Group sold 112 ArriVent BioPharma shares in Q2 2026, an estimated $3.31K.
  • ArriVent BioPharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4228 holding.
  • PNC Financial Services Group first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's ArriVent BioPharma position peaked at $7.52K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.